-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody that can selectively target CD20-positive B cells
Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody that can selectively target CD20 positive B cells Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody that can selectively target CD20 positive B cells
At present, Ocrelizumab has received FDA approval for the treatment of multiple sclerosis
The safety of FDA Ocrelizumab for patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis for up to 7 years
The safety analysis is based on the comprehensive clinical and laboratory data of all patients treated with Ocrelizumab in 11 clinical trials (including phase 2, phase 3, and phase 3b trials)
Infect
Annual incidence of severe infections
Annual incidence of severe infectionsAs of January 2020, a total of 5,680 multiple sclerosis patients have received Ocrelizumab treatment (18,218 patients·years were exposed [PY])
5680 multiple sclerosis patients received Ocrelizumab treatment 5680 multiple sclerosis patients received Ocrelizumab treatment During the phase 3 trial treatment, the incidence of adverse events in the Ocrelizumab group was similar to that in the control group.
Original source:
Original source:Hauser Stephen L,Kappos Ludwig,Montalban Xavier et al.
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
in this message
